"","AA_POS","MUTATION","GENE_ID","ALLELE.COUNT","Pathogenic","Genomic_location","ProteinID","MUTPRED.Score","Hypothesis","ALLELE.COUNT.log","AA","a4v","HSA","NHSA","a4vAHS","ConSurf_index"
"1",5,"R5C","MAPT",2,"","17:44039716:C:T","P10636",166.646341463415,"Gain of catalytic residue at E7 (P = 0.0864); Loss of disorder (P = 0.1946); Loss of glycosylation at P4 (P = 0.2166); Loss of solvent accessibility (P = 0.3854); Gain of sheet (P = 0.6509)",0.693147180559945,"R",279.330052990159,0,0,0,17.5304054054054
"2",5,"R5L","MAPT",0.1,"P","17:44039717:G:T","P10636",215.365853658537,"Gain of stability (P = 0.0485); Loss of disorder (P = 0.1465); Loss of solvent accessibility (P = 0.1922); Loss of glycosylation at P4 (P = 0.2241); Gain of catalytic residue at E9 (P = 0.2984)",-2.30258509299405,"R",279.330052990159,0,0,0,17.5304054054054
"3",13,"D13N","MAPT",1,"","17:44039740:G:A","P10636",147.158536585366,"Loss of phosphorylation at T17 (P = 0.1333); Loss of stability (P = 0.2348); Gain of relative solvent accessibility (P = 0.2363); Loss of disorder (P = 0.2447); Gain of glycosylation at T17 (P = 0.3274)",0,"D",444.952308856927,0,0,0,17.1670997920998
"4",16,"G16V","MAPT",1,"","17:44039750:G:T","P10636",166.646341463415,"Loss of catalytic residue at A15 (P = 0.0601); Loss of disorder (P = 0.0672); Loss of phosphorylation at T17 (P = 0.2248); Loss of glycosylation at T17 (P = 0.3836); Loss of relative solvent accessibility (P = 0.5582)",0,"G",366.63890991673,0,0,0,202.452962577963
"5",17,"T17S","MAPT",1,"","17:44039752:A:T","P10636",30.2317073170732,"Loss of glycosylation at T17 (P = 0.1704); Loss of phosphorylation at T17 (P = 0.1742); Gain of disorder (P = 0.529); Gain of MoRF binding (P = 0.6153); Loss of stability (P = 0.629)",0,"T",234.352763058289,0,0,0,357.947765072765
"6",19,"G19R","MAPT",4,"","17:44039758:G:A","P10636",137.414634146341,"Gain of solvent accessibility (P = 0.0456); Gain of MoRF binding (P = 0.0644); Loss of glycosylation at K24 (P = 0.0926); Loss of catalytic residue at L20 (P = 0.1423); Loss of methylation at K24 (P = 0.1742)",1.38629436111989,"G",286.208932626798,0,0,0,244.414760914761
"7",19,"G19R","MAPT",4,"","17:44039758:G:C","P10636",137.414634146341,"Gain of solvent accessibility (P = 0.0456); Gain of MoRF binding (P = 0.0644); Loss of glycosylation at K24 (P = 0.0926); Loss of catalytic residue at L20 (P = 0.1423); Loss of methylation at K24 (P = 0.1742)",1.38629436111989,"G",286.208932626798,0,0,0,244.414760914761
"8",21,"G21V","MAPT",3,"","17:44039765:G:T","P10636",98.4390243902439,"Loss of disorder (P = 0.0978); Loss of glycosylation at K24 (P = 0.1772); Loss of phosphorylation at T17 (P = 0.1993); Gain of catalytic residue at G21 (P = 0.3438); Gain of solvent accessibility (P = 0.3602)",1.09861228866811,"G",189.904617713853,0,0,0,325.795218295218
"9",22,"D22N","MAPT",2,"","17:44039767:G:A","P10636",39.9756097560976,"Loss of solvent accessibility (P = 0.1202); Loss of glycosylation at K24 (P = 0.1604); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.1996); Loss of phosphorylation at T17 (P = 0.2205)",0.693147180559945,"D",189.904617713853,0,0,0,269.301195426195
"10",27,"G27E","MAPT",9,"","17:44039783:G:A","P10636",10.7439024390244,"Gain of solvent accessibility (P = 0.012); Gain of relative solvent accessibility (P = 0.0479); Gain of glycosylation at T30 (P = 0.1208); Gain of phosphorylation at Y29 (P = 0.3154); Loss of catalytic residue at K24 (P = 0.3671)",2.19722457733622,"G",143.339894019682,0,0,0,179.928014553015
"11",30,"T30A","MAPT",8,"","17:44039791:A:G","P10636",88.6951219512195,"Gain of catalytic residue at T30 (P = 0.0361); Loss of glycosylation at T30 (P = 0.0649); Gain of phosphorylation at Y29 (P = 0.3204); Gain of MoRF binding (P = 0.6346); Loss of sheet (P = 0.6423)",2.07944154167984,"T",129.582134746404,0,0,0,142.870841995842
"12",36,"E36D","MAPT",3,"","17:44039811:G:T","P10636",30.2317073170732,"Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at E36 (P = 0.4216); Gain of solvent accessibility (P = 0.4496); Gain of glycosylation at T39 (P = 0.458); Loss of stability (P = 0.4664)",1.09861228866811,"E",1,0,0,0,500.726871101871
"13",36,"E36D","MAPT",3,"","17:44039811:G:C","P10636",30.2317073170732,"Gain of relative solvent accessibility (P = 0.2363); Loss of catalytic residue at E36 (P = 0.4216); Gain of solvent accessibility (P = 0.4496); Gain of glycosylation at T39 (P = 0.458); Loss of stability (P = 0.4664)",1.09861228866811,"E",1,0,0,0,500.726871101871
"14",39,"T39M","MAPT",3,"","17:44039819:C:T","P10636",1,"Loss of phosphorylation at T39 (P = 0.0141); Loss of glycosylation at T39 (P = 0.1546); Loss of methylation at K44 (P = 0.2417); Gain of ubiquitination at K44 (P = 0.4079); Gain of solvent accessibility (P = 0.5334)",1.09861228866811,"T",61.8516275548827,0,0,0,649.318866943867
"15",45,"E45V","MAPT",4,"","17:44049225:A:T","P10636",69.2073170731707,"Loss of solvent accessibility (P = 0.0052); Loss of relative solvent accessibility (P = 0.0404); Loss of glycosylation at K44 (P = 0.1626); Loss of phosphorylation at S46 (P = 0.1767); Gain of stability (P = 0.2909)",1.38629436111989,"E",300.495836487509,0,0,0,256.222193347193
"16",47,"P47S","MAPT",1,"","17:44049230:C:T","P10636",59.4634146341463,"Gain of phosphorylation at P47 (P = 0.023); Gain of relative solvent accessibility (P = 0.09); Loss of glycosylation at T50 (P = 0.1265); Gain of solvent accessibility (P = 0.1903); Gain of catalytic residue at L43 (P = 0.2523)",0,"P",366.63890991673,0,0,0,253.679054054054
"17",48,"L48V","MAPT",1,"","17:44049233:C:G","P10636",10.7439024390244,"Gain of glycosylation at S46 (P = 0.146); Loss of catalytic residue at L48 (P = 0.201); Gain of methylation at K44 (P = 0.3482); Loss of stability (P = 0.395); Loss of ubiquitination at K44 (P = 0.4035)",0,"L",324.307342922029,0,0,0,257.493762993763
"18",52,"T52A","MAPT",1,"","17:44049245:A:G","P10636",20.4878048780488,"Loss of glycosylation at T52 (P = 0.0074); Loss of phosphorylation at T52 (P = 0.013); Loss of catalytic residue at L48 (P = 0.4931); Loss of stability (P = 0.6309); Loss of sheet (P = 0.6423)",0,"T",188.846328538986,0,0,0,240.600051975052
"19",60,"G60V","MAPT",1,"","17:44049270:G:T","P10636",30.2317073170732,"Loss of relative solvent accessibility (P = 0.0404); Gain of glycosylation at T63 (P = 0.0848); Loss of solvent accessibility (P = 0.2668); Loss of phosphorylation at T63 (P = 0.5578); Gain of stability (P = 0.6106)",0,"G",83.5465556396669,0,0,0,226.794438669439
"20",67,"K67R","MAPT",1,"","17:44049291:A:G","P10636",108.182926829268,"Loss of ubiquitination at K67 (P = 0.0012); Loss of methylation at K67 (P = 0.0123); Loss of solvent accessibility (P = 0.1115); Loss of glycosylation at K67 (P = 0.1378); Loss of relative solvent accessibility (P = 0.1807)",0,"K",221.124148372445,0,0,0,112.35317047817
"21",69,"T69A","MAPT",2,"","17:44049296:A:G","P10636",20.4878048780488,"Loss of phosphorylation at T69 (P = 0.0064); Loss of glycosylation at T69 (P = 0.0112); Loss of methylation at K67 (P = 0.2501); Loss of stability (P = 0.3968); Gain of ubiquitination at K67 (P = 0.4036)",0.693147180559945,"T",140.694171082513,0,0,0,80.9272349272349
"22",71,"T71R","MAPT",1,"","17:44049303:C:G","P10636",59.4634146341463,"Loss of phosphorylation at T71 (P = 0.0148); Loss of glycosylation at T71 (P = 0.0155); Loss of methylation at K67 (P = 0.0519); Gain of solvent accessibility (P = 0.2291); Gain of ubiquitination at K67 (P = 0.4036)",0,"T",312.137017411052,0,0,0,78.3840956340956
"23",75,"V75A","MAPT",1,"","17:44051754:T:C","P10636",10.7439024390244,"Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at T76 (P = 0.1803); Gain of solvent accessibility (P = 0.3956); Gain of phosphorylation at T71 (P = 0.5089); Loss of stability (P = 0.618)",0,"V",505.803936411809,0.044,0,0.024,273.47920997921
"24",76,"T76I","MAPT",6,"","17:44051757:C:T","P10636",156.90243902439,"Loss of phosphorylation at T76 (P = 0.015); Loss of glycosylation at T76 (P = 0.0255); Gain of catalytic residue at P78 (P = 0.0307); Loss of solvent accessibility (P = 0.5485); Loss of relative solvent accessibility (P = 0.5582)",1.79175946922805,"T",433.311127933384,0,0,0,72.7528586278586
"25",76,"T76K","MAPT",6,"","17:44051757:C:A","P10636",166.646341463415,"Gain of ubiquitination at T76 (P = 0.0025); Gain of methylation at T76 (P = 0.0043); Loss of phosphorylation at T76 (P = 0.015); Gain of solvent accessibility (P = 0.0156); Gain of relative solvent accessibility (P = 0.0479)",1.79175946922805,"T",433.311127933384,0,0,0,72.7528586278586
"26",78,"P78A","MAPT",2,"","17:44051762:C:G","P10636",117.926829268293,"Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of stability (P = 0.2186); Gain of glycosylation at T76 (P = 0.2376); Loss of phosphorylation at T76 (P = 0.4686)",0.693147180559945,"P",349.177138531416,0,0,0,127.067047817048
"27",78,"P78T","MAPT",2,"","17:44051762:C:A","P10636",117.926829268293,"Gain of glycosylation at P78 (P = 0.0304); Gain of phosphorylation at P78 (P = 0.0545); Loss of stability (P = 0.1627); Loss of relative solvent accessibility (P = 0.1807); Loss of solvent accessibility (P = 0.1922)",0.693147180559945,"P",349.177138531416,0,0,0,127.067047817048
"28",82,"E82D","MAPT",1,"","17:44051776:G:C","P10636",49.719512195122,"Loss of methylation at K87 (P = 0.128); Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K87 (P = 0.2757); Loss of stability (P = 0.3582); Loss of ubiquitination at K87 (P = 0.3786)",0,"E",348.118849356548,0,0,0,98.5475571725571
"29",82,"E82D","MAPT",1,"","17:44051776:G:T","P10636",49.719512195122,"Loss of methylation at K87 (P = 0.128); Loss of solvent accessibility (P = 0.1813); Loss of glycosylation at K87 (P = 0.2757); Loss of stability (P = 0.3582); Loss of ubiquitination at K87 (P = 0.3786)",0,"E",348.118849356548,0,0,0,98.5475571725571
"30",82,"E82K","MAPT",1,"","17:44051774:G:A","P10636",195.878048780488,"Gain of ubiquitination at E82 (P = 0.0018); Gain of methylation at E82 (P = 0.0093); Gain of glycosylation at E82 (P = 0.0173); Loss of stability (P = 0.1837); Loss of catalytic residue at D81 (P = 0.3096)",0,"E",348.118849356548,0,0,0,98.5475571725571
"31",90,"A90V","MAPT",2,"","17:44051799:C:T","P10636",30.2317073170732,"Gain of methylation at K87 (P = 0.0692); Loss of phosphorylation at T95 (P = 0.193); Loss of glycosylation at K87 (P = 0.2202); Loss of ubiquitination at K87 (P = 0.3786); Gain of sheet (P = 0.6509)",0.693147180559945,"A",209.482967448902,0,0,0,218.256756756757
"32",91,"A91V","MAPT",8,"","17:44051802:C:T","P10636",59.4634146341463,"Loss of relative solvent accessibility (P = 0.0404); Gain of methylation at K87 (P = 0.089); Loss of solvent accessibility (P = 0.1301); Loss of glycosylation at K87 (P = 0.1817); Loss of phosphorylation at T95 (P = 0.1849)",2.07944154167984,"A",157.626797880394,0,0,0,94.7328482328482
"33",93,"P93L","MAPT",1,"","17:44051808:C:T","P10636",49.719512195122,"Loss of phosphorylation at T95 (P = 0.0932); Loss of glycosylation at T95 (P = 0.1079); Gain of catalytic residue at P93 (P = 0.3085); Gain of solvent accessibility (P = 0.571); Gain of sheet (P = 0.6509)",0,"P",299.966691900076,0,0,0,370.300155925156
"34",102,"T102R","MAPT",1,"","17:44051835:C:G","P10636",117.926829268293,"Loss of glycosylation at T102 (P = 0.022); Loss of phosphorylation at T102 (P = 0.0651); Gain of solvent accessibility (P = 0.0808); Loss of catalytic residue at T102 (P = 0.1481); Gain of relative solvent accessibility (P = 0.2363)",0,"T",290.442089326268,0,0,0,52.5893970893971
"35",107,"G107S","MAPT",1,"","17:44055752:G:A","P10636",69.2073170731707,"Gain of glycosylation at G107 (P = 0.0026); Gain of phosphorylation at G107 (P = 0.015); Loss of stability (P = 0.1459); Loss of catalytic residue at A106 (P = 0.1516); Gain of solvent accessibility (P = 0.3956)",0,"G",270.334595003785,0,0,0,101.99896049896
"36",107,"G107V","MAPT",9,"","17:44055753:G:T","P10636",127.670731707317,"Loss of catalytic residue at A106 (P = 0.1576); Loss of phosphorylation at T102 (P = 0.2096); Loss of glycosylation at T102 (P = 0.2467); Loss of stability (P = 0.5525); Loss of relative solvent accessibility (P = 0.5582)",2.19722457733622,"G",270.334595003785,0,0,0,101.99896049896
"37",116,"D116E","MAPT",3,"","17:44055781:C:G","P10636",59.4634146341463,"Loss of glycosylation at S113 (P = 0.1671); Gain of phosphorylation at S113 (P = 0.2724); Gain of solvent accessibility (P = 0.3089); Loss of catalytic residue at H121 (P = 0.5061); Gain of sheet (P = 0.6509)",1.09861228866811,"D",218.478425435276,0,0,0,72.2079002079002
"38",116,"D116E","MAPT",3,"","17:44055781:C:A","P10636",59.4634146341463,"Loss of glycosylation at S113 (P = 0.1671); Gain of phosphorylation at S113 (P = 0.2724); Gain of solvent accessibility (P = 0.3089); Loss of catalytic residue at H121 (P = 0.5061); Gain of sheet (P = 0.6509)",1.09861228866811,"D",218.478425435276,0,0,0,72.2079002079002
"39",125,"E125K","MAPT",1,"","17:44055806:G:A","P10636",117.926829268293,"Gain of ubiquitination at E125 (P = 9e-04); Gain of methylation at E125 (P = 0.0252); Gain of glycosylation at E125 (P = 0.0342); Gain of relative solvent accessibility (P = 0.0999); Gain of solvent accessibility (P = 0.1045)",0,"E",190.962906888721,0,0,0,227.157744282744
"40",126,"P126S","MAPT",6,"","17:44060546:C:T","P10636",147.158536585366,"Gain of phosphorylation at P126 (P = 0.0388); Loss of glycosylation at T123 (P = 0.0516); Gain of relative solvent accessibility (P = 0.2629); Loss of methylation at K130 (P = 0.312); Gain of ubiquitination at K130 (P = 0.3527)",1.79175946922805,"P",293.087812263437,0,0,0,321.072245322245
"41",137,"L137P","MAPT",3,"","17:44060580:T:C","P10636",117.926829268293,"Gain of glycosylation at L137 (P = 0.0382); Gain of relative solvent accessibility (P = 0.0479); Loss of stability (P = 0.0616); Gain of solvent accessibility (P = 0.1376); Gain of catalytic residue at L137 (P = 0.3359)",1.09861228866811,"L",381.984102952309,0,0,0,231.335758835759
"42",166,"A166V","MAPT",1,"","17:44060667:C:T","P10636",88.6951219512195,"Loss of glycosylation at T167 (P = 0.1428); Loss of methylation at R164 (P = 0.4053); Gain of solvent accessibility (P = 0.5334); Loss of phosphorylation at S171 (P = 0.6134); Gain of MoRF binding (P = 0.7468)",0,"A",97.3043149129448,0,0,0,180.654625779626
"43",168,"R168C","MAPT",3,"","17:44060672:C:T","P10636",147.158536585366,"Loss of phosphorylation at S171 (P = 0.0775); Loss of catalytic residue at R168 (P = 0.0837); Gain of glycosylation at T167 (P = 0.112); Loss of solvent accessibility (P = 0.3854); Gain of methylation at R164 (P = 0.4204)",1.09861228866811,"R",157.626797880394,0,0,0,669.663981288981
"44",177,"D177N","MAPT",1,"","17:44060699:G:A","P10636",108.182926829268,"Loss of solvent accessibility (P = 0.1202); Loss of relative solvent accessibility (P = 0.1807); Gain of glycosylation at T178 (P = 0.2384); Gain of catalytic residue at D177 (P = 0.2746); Gain of methylation at R182 (P = 0.4144)",0,"D",75.0802422407267,0,0,0,147.412162162162
"45",177,"D177V","MAPT",13,"","17:44060700:A:T","P10636",108.182926829268,"Loss of solvent accessibility (P = 0.0544); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at T178 (P = 0.144); Gain of catalytic residue at E176 (P = 0.3132); Gain of methylation at R182 (P = 0.3623)",2.56494935746154,"D",75.0802422407267,0,0,0,147.412162162162
"46",181,"G181S","MAPT",1,"","17:44060711:G:A","P10636",108.182926829268,"Gain of phosphorylation at G181 (P = 0.0146); Gain of glycosylation at G181 (P = 0.0648); Loss of relative solvent accessibility (P = 0.0981); Loss of stability (P = 0.3729); Loss of solvent accessibility (P = 0.3854)",0,"G",14.7577592732778,0,0,0,252.407484407484
"47",184,"A184T","MAPT",2,"","17:44060720:G:A","P10636",88.6951219512195,"Gain of phosphorylation at A184 (P = 0.0111); Gain of methylation at K189 (P = 0.1037); Loss of glycosylation at K189 (P = 0.1968); Gain of ubiquitination at K189 (P = 0.3023); Gain of catalytic residue at A184 (P = 0.41)",0.693147180559945,"A",266.630582891749,0,0,0,697.093555093555
"48",195,"D195G","MAPT",1,"","17:44060754:A:G","P10636",283.573170731707,"Gain of helix (P = 0.0022); Loss of loop (P = 0.0022); Loss of solvent accessibility (P = 0.0674); Loss of stability (P = 0.1446); Gain of catalytic residue at L196 (P = 0.2532)",0,"D",266.630582891749,0,0,0,519.800415800416
"49",197,"H197Q","MAPT",1,"","17:44060761:C:G","P10636",137.414634146341,"Loss of catalytic residue at L196 (P = 0.2224); Gain of glycosylation at P201 (P = 0.2469); Gain of MoRF binding (P = 0.5396); Gain of solvent accessibility (P = 0.5485); Loss of stability (P = 0.5995)",0,"H",343.356548069644,0,0,0,665.304313929314
"50",197,"H197Q","MAPT",1,"","17:44060761:C:A","P10636",137.414634146341,"Loss of catalytic residue at L196 (P = 0.2224); Gain of glycosylation at P201 (P = 0.2469); Gain of MoRF binding (P = 0.5396); Gain of solvent accessibility (P = 0.5485); Loss of stability (P = 0.5995)",0,"H",343.356548069644,0,0,0,665.304313929314
"51",200,"G200A","MAPT",4,"","17:44060769:G:C","P10636",98.4390243902439,"Loss of catalytic residue at G200 (P = 0.2691); Loss of glycosylation at K204 (P = 0.2791); Gain of ubiquitination at K204 (P = 0.3757); Loss of methylation at K204 (P = 0.4366); Gain of solvent accessibility (P = 0.5093)",1.38629436111989,"G",232.236184708554,0,0,0,298.002338877339
"52",200,"G200E","MAPT",4,"","17:44060769:G:A","P10636",156.90243902439,"Gain of solvent accessibility (P = 0.0026); Gain of relative solvent accessibility (P = 0.0166); Gain of glycosylation at P201 (P = 0.2128); Loss of catalytic residue at E199 (P = 0.3416); Gain of ubiquitination at K204 (P = 0.3757)",1.38629436111989,"G",232.236184708554,0,0,0,298.002338877339
"53",200,"G200W","MAPT",2,"","17:44060768:G:T","P10636",137.414634146341,"Loss of glycosylation at K204 (P = 0.2595); Loss of ubiquitination at K204 (P = 0.3654); Gain of MoRF binding (P = 0.3772); Gain of methylation at K204 (P = 0.4499); Loss of catalytic residue at L203 (P = 0.4973)",0.693147180559945,"G",232.236184708554,0,0,0,298.002338877339
"54",202,"P202Q","MAPT",17431,"","17:44060775:C:A","P10636",429.731707317073,"Loss of glycosylation at P201 (P = 0.1774); Loss of catalytic residue at P201 (P = 0.2509); Gain of solvent accessibility (P = 0.3418); Loss of ubiquitination at K204 (P = 0.3501); Gain of MoRF binding (P = 0.376)",9.76600550921487,"P",226.944738834217,0,0,0,603.724012474012
"55",203,"L203P","MAPT",1,"","17:44060778:T:C","P10636",225.109756097561,"Gain of relative solvent accessibility (P = 0.0249); Gain of helix (P = 0.0349); Gain of glycosylation at L203 (P = 0.0443); Gain of catalytic residue at P202 (P = 0.0519); Loss of loop (P = 0.0603)",0,"L",250.756245268736,0,0,0,670.027286902287
"56",204,"K204Q","MAPT",1,"","17:44060780:A:C","P10636",264.085365853659,"Loss of ubiquitination at K204 (P = 0.0023); Loss of methylation at K204 (P = 0.0031); Loss of glycosylation at K204 (P = 0.0194); Loss of solvent accessibility (P = 0.0561); Loss of relative solvent accessibility (P = 0.1807)",0,"K",265.043149129447,0,0,0,272.20764033264
"57",205,"G205W","MAPT",2,"","17:44060783:G:T","P10636",283.573170731707,"Loss of relative solvent accessibility (P = 0.0676); Loss of glycosylation at K204 (P = 0.0988); Gain of catalytic residue at L203 (P = 0.1365); Gain of ubiquitination at K209 (P = 0.3433); Gain of MoRF binding (P = 0.3557)",0.693147180559945,"G",265.043149129447,0,0,0,507.084719334719
"58",209,"K209R","MAPT",1,"","17:44060796:A:G","P10636",225.109756097561,"Loss of ubiquitination at K209 (P = 0.0039); Loss of methylation at K209 (P = 0.0169); Loss of glycosylation at K209 (P = 0.0391); Gain of stability (P = 0.3568); Gain of solvent accessibility (P = 0.4067)",0,"K",141.223315669947,0,0,0,166.304054054054
"59",213,"G213R","MAPT",466,"","17:44060807:G:C","P10636",244.59756097561,"Gain of solvent accessibility (P = 0.0037); Loss of methylation at K215 (P = 0.0468); Loss of glycosylation at K215 (P = 0.0635); Gain of ubiquitination at K209 (P = 0.3459); Gain of MoRF binding (P = 0.3944)",6.14418563412565,"G",134.873580620742,0,0,0,403.179313929314
"60",217,"E217V","MAPT",1,"","17:44060820:A:T","P10636",225.109756097561,"Gain of glycosylation at S214 (P = 0.0589); Loss of solvent accessibility (P = 0.1986); Gain of methylation at K215 (P = 0.2257); Gain of ubiquitination at K215 (P = 0.3565); Loss of relative solvent accessibility (P = 0.3919)",0,"E",29.0446631339894,0,0,0,252.77079002079
"61",222,"R222C","MAPT",30,"","17:44060834:C:T","P10636",273.829268292683,"Gain of catalytic residue at V224 (P = 0.0626); Gain of glycosylation at S227 (P = 0.1553); Loss of solvent accessibility (P = 0.1744); Loss of stability (P = 0.2382); Loss of relative solvent accessibility (P = 0.5582)",3.40119738166216,"R",15.8160484481454,0,0,0,141.962577962578
"62",223,"D223N","MAPT",5,"","17:44060837:G:A","P10636",69.2073170731707,"Loss of stability (P = 0.1812); Loss of glycosylation at S228 (P = 0.2653); Gain of methylation at R222 (P = 0.6599); Loss of phosphorylation at S227 (P = 0.7447); Gain of MoRF binding (P = 0.8691)",1.6094379124341,"D",69.2596517789553,0,0,0,98.3659043659044
"63",225,"D225N","MAPT",2,"","17:44060843:G:A","P10636",176.390243902439,"Gain of glycosylation at S228 (P = 0.2879); Loss of stability (P = 0.3151); Gain of catalytic residue at D225 (P = 0.3717); Loss of solvent accessibility (P = 0.6392); Gain of methylation at R222 (P = 0.6551)",0.693147180559945,"D",5.76230128690386,0,0,0,45.6865904365904
"64",228,"S228F","MAPT",2,"","17:44060853:C:T","P10636",283.573170731707,"Loss of phosphorylation at S228 (P = 0.0013); Loss of glycosylation at S228 (P = 0.0526); Loss of relative solvent accessibility (P = 0.5582); Loss of solvent accessibility (P = 0.6498); Gain of sheet (P = 0.6509)",0.693147180559945,"S",103.124905374716,0,0,0,155.586538461538
"65",232,"S232C","MAPT",2,"","17:44060865:C:G","P10636",176.390243902439,"Loss of phosphorylation at S232 (P = 0.0015); Loss of glycosylation at S232 (P = 0.0211); Gain of catalytic residue at S232 (P = 0.073); Loss of methylation at K236 (P = 0.2331); Gain of ubiquitination at K236 (P = 0.2713)",0.693147180559945,"S",194.137774413323,0,0,0,115.804573804574
"66",232,"S232F","MAPT",2,"","17:44060865:C:T","P10636",166.646341463415,"Loss of phosphorylation at S232 (P = 0.0015); Loss of glycosylation at S232 (P = 0.0211); Gain of ubiquitination at K236 (P = 0.2483); Loss of methylation at K236 (P = 0.2521); Loss of MoRF binding (P = 0.8489)",0.693147180559945,"S",194.137774413323,0,0,0,115.804573804574
"67",233,"P233R","MAPT",1,"","17:44060868:C:G","P10636",186.134146341463,"Loss of glycosylation at P233 (P = 0.0326); Gain of solvent accessibility (P = 0.0789); Loss of catalytic residue at P233 (P = 0.1666); Gain of methylation at K236 (P = 0.2088); Gain of relative solvent accessibility (P = 0.2363)",0,"P",194.137774413323,0,0,0,329.609927234927
"68",236,"K236E","MAPT",2,"","17:44060876:A:G","P10636",244.59756097561,"Loss of ubiquitination at K236 (P = 0.0067); Loss of methylation at K236 (P = 0.0087); Loss of glycosylation at K236 (P = 0.099); Gain of relative solvent accessibility (P = 0.1571); Loss of catalytic residue at K236 (P = 0.1785)",0.693147180559945,"K",206.837244511734,0,0,0,254.405665280665
"69",237,"A237T","MAPT",2,"","17:44060879:G:A","P10636",225.109756097561,"Gain of phosphorylation at A237 (P = 0.0065); Gain of glycosylation at A237 (P = 0.0157); Loss of relative solvent accessibility (P = 0.0404); Loss of solvent accessibility (P = 0.1301); Gain of methylation at K236 (P = 0.2146)",0.693147180559945,"A",206.837244511734,0,0,0,543.051975051975
"70",242,"D242G","MAPT",1,"","17:44060895:A:G","P10636",49.719512195122,"Loss of solvent accessibility (P = 0.0477); Gain of glycosylation at P245 (P = 0.1257); Gain of methylation at R244 (P = 0.1611); Loss of relative solvent accessibility (P = 0.1807); Gain of catalytic residue at G243 (P = 0.2744)",0,"D",135.402725208176,0,0,0,466.394490644491
"71",243,"G243R","MAPT",1,"","17:44060897:G:C","P10636",147.158536585366,"Gain of solvent accessibility (P = 0.019); Gain of glycosylation at P245 (P = 0.0542); Loss of catalytic residue at P239 (P = 0.0914); Loss of methylation at R244 (P = 0.2792); Gain of MoRF binding (P = 0.3095)",0,"G",129.052990158971,0,0,0,474.75051975052
"72",243,"G243R","MAPT",1,"","17:44060897:G:A","P10636",147.158536585366,"Gain of solvent accessibility (P = 0.019); Gain of glycosylation at P245 (P = 0.0542); Loss of catalytic residue at P239 (P = 0.0914); Loss of methylation at R244 (P = 0.2792); Gain of MoRF binding (P = 0.3095)",0,"G",129.052990158971,0,0,0,474.75051975052
"73",244,"R244L","MAPT",4,"","17:44060901:G:T","P10636",137.414634146341,"Gain of glycosylation at T248 (P = 0.1379); Loss of methylation at R244 (P = 0.1946); Gain of catalytic residue at R244 (P = 0.201); Loss of solvent accessibility (P = 0.3103); Loss of MoRF binding (P = 0.5475)",1.38629436111989,"R",141.752460257381,0,0,0,387.920478170478
"74",248,"T248R","MAPT",1,"","17:44060913:C:G","P10636",137.414634146341,"Loss of phosphorylation at T248 (P = 0.0023); Loss of glycosylation at T248 (P = 0.0308); Gain of solvent accessibility (P = 0.0503); Gain of MoRF binding (P = 0.1103); Loss of methylation at R244 (P = 0.3682)",0,"T",176.146858440575,0,0,0,330.699844074844
"75",257,"P257A","MAPT",1,"","17:44060939:C:G","P10636",205.621951219512,"Loss of glycosylation at T254 (P = 0.0947); Loss of stability (P = 0.1189); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of phosphorylation at S255 (P = 0.2339)",0,"P",446.010598031794,0,0,0,671.117203742204
"76",261,"A261V","MAPT",3,"","17:44060952:C:T","P10636",108.182926829268,"Loss of relative solvent accessibility (P = 0.0981); Loss of solvent accessibility (P = 0.2517); Gain of catalytic residue at A261 (P = 0.4116); Loss of disorder (P = 0.5951); Loss of glycosylation at P257 (P = 0.6194)",1.09861228866811,"A",581.471612414837,0.837,0.167,0.147,364.123960498961
"77",262,"E262G","MAPT",1,"","17:44060955:A:G","P10636",176.390243902439,"Loss of solvent accessibility (P = 0.0187); Gain of catalytic residue at A261 (P = 0.088); Loss of stability (P = 0.0949); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at P257 (P = 0.6425)",0,"E",560.305828917487,0.837,0.167,0.147,614.441528066528
"78",266,"P266T","MAPT",1,"","17:44060966:C:A","P10636",205.621951219512,"Loss of catalytic residue at L267 (P = 0.2168); Gain of phosphorylation at P266 (P = 0.2524); Loss of disorder (P = 0.303); Gain of glycosylation at P266 (P = 0.3518); Loss of relative solvent accessibility (P = 0.5582)",0,"P",590.467070401211,0,0,0,209.900727650728
"79",267,"L267V","MAPT",1,"","17:44060969:C:G","P10636",98.4390243902439,"Loss of catalytic residue at L267 (P = 0.1113); Loss of stability (P = 0.4986); Gain of disorder (P = 0.5645); Loss of sheet (P = 0.6423); Gain of MoRF binding (P = 0.8504)",0,"L",658.726722180167,0.333,0,0.313,306.358367983368
"80",273,"S273A","MAPT",4,"","17:44060987:T:G","P10636",127.670731707317,"Loss of glycosylation at S273 (P = 0.0281); Loss of phosphorylation at S273 (P = 0.0923); Loss of disorder (P = 0.1791); Loss of stability (P = 0.1875); Loss of methylation at K274 (P = 0.1956)",1.38629436111989,"S",544.431491294474,2.652,0.295,0.275,348.683471933472
"81",273,"S273F","MAPT",1,"","17:44060988:C:T","P10636",195.878048780488,"Loss of glycosylation at S273 (P = 0.0281); Loss of disorder (P = 0.0351); Gain of methylation at K274 (P = 0.0726); Loss of phosphorylation at S273 (P = 0.0923); Loss of relative solvent accessibility (P = 0.0981)",0,"S",544.431491294474,2.652,0.295,0.275,348.683471933472
"82",273,"S273P","MAPT",4,"","17:44060987:T:C","P10636",78.9512195121951,"Loss of glycosylation at S273 (P = 0.0453); Loss of stability (P = 0.0785); Loss of phosphorylation at S273 (P = 0.0923); Gain of methylation at K274 (P = 0.1154); Gain of catalytic residue at L272 (P = 0.2005)",1.38629436111989,"S",544.431491294474,2.652,0.295,0.275,348.683471933472
"83",280,"P280A","MAPT",1,"","17:44061008:C:G","P10636",137.414634146341,"Loss of glycosylation at T277 (P = 0.0601); Loss of disorder (P = 0.1501); Loss of phosphorylation at T277 (P = 0.1697); Gain of catalytic residue at D285 (P = 0.4101); Loss of stability (P = 0.5542)",0,"P",363.464042392127,0,0,0,627.702182952183
"84",285,"D285E","MAPT",14849,"","17:44061025:C:G","P10636",117.926829268293,"Gain of glycosylation at P284 (P = 0.095); Gain of solvent accessibility (P = 0.2601); Gain of catalytic residue at D285 (P = 0.3212); Gain of phosphorylation at S282 (P = 0.3588); Gain of disorder (P = 0.4968)",9.60568780189606,"D",284.092354277063,0,0,0,700
"85",285,"D285E","MAPT",14849,"","17:44061025:C:A","P10636",117.926829268293,"Gain of glycosylation at P284 (P = 0.095); Gain of solvent accessibility (P = 0.2601); Gain of catalytic residue at D285 (P = 0.3212); Gain of phosphorylation at S282 (P = 0.3588); Gain of disorder (P = 0.4968)",9.60568780189606,"D",284.092354277063,0,0,0,700
"86",286,"G286R","MAPT",1,"","17:44061026:G:A","P10636",127.670731707317,"Loss of glycosylation at S282 (P = 0.0846); Gain of solvent accessibility (P = 0.1319); Loss of phosphorylation at S282 (P = 0.2806); Loss of catalytic residue at G286 (P = 0.2913); Loss of methylation at R291 (P = 0.3238)",0,"G",240.173353520061,0,0,0,515.622401247401
"87",286,"G286R","MAPT",1,"","17:44061026:G:C","P10636",127.670731707317,"Loss of glycosylation at S282 (P = 0.0846); Gain of solvent accessibility (P = 0.1319); Loss of phosphorylation at S282 (P = 0.2806); Loss of catalytic residue at G286 (P = 0.2913); Loss of methylation at R291 (P = 0.3238)",0,"G",240.173353520061,0,0,0,515.622401247401
"88",287,"P287L","MAPT",1,"","17:44061030:C:T","P10636",127.670731707317,"Loss of disorder (P = 0.0753); Loss of glycosylation at S288 (P = 0.0949); Gain of catalytic residue at P287 (P = 0.1806); Loss of phosphorylation at S282 (P = 0.1957); Gain of methylation at R291 (P = 0.2334)",0,"P",240.173353520061,0,0,0,377.384615384615
"89",287,"P287S","MAPT",1,"","17:44061029:C:T","P10636",98.4390243902439,"Gain of glycosylation at P287 (P = 0.0317); Gain of phosphorylation at P287 (P = 0.0339); Gain of methylation at R291 (P = 0.3123); Loss of stability (P = 0.323); Gain of disorder (P = 0.4926)",0,"P",240.173353520061,0,0,0,377.384615384615
"90",290,"G290R","MAPT",1,"","17:44061038:G:C","P10636",186.134146341463,"Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K293 (P = 0.1041); Gain of methylation at K293 (P = 0.1582); Loss of glycosylation at S288 (P = 0.1871); Loss of catalytic residue at R291 (P = 0.3107)",0,"G",208.424678274035,0,0,0,391.735187110187
"91",290,"G290R","MAPT",1,"","17:44061038:G:A","P10636",186.134146341463,"Gain of solvent accessibility (P = 0.0037); Loss of ubiquitination at K293 (P = 0.1041); Gain of methylation at K293 (P = 0.1582); Loss of glycosylation at S288 (P = 0.1871); Loss of catalytic residue at R291 (P = 0.3107)",0,"G",208.424678274035,0,0,0,391.735187110187
"92",291,"R291W","MAPT",10,"","17:44061041:C:T","P10636",264.085365853659,"Loss of solvent accessibility (P = 0.0087); Loss of disorder (P = 0.0149); Gain of methylation at K293 (P = 0.089); Loss of phosphorylation at S288 (P = 0.0958); Loss of relative solvent accessibility (P = 0.0981)",2.30258509299405,"R",208.424678274035,0,0,0,693.823804573805
"93",293,"K293E","MAPT",1,"","17:44061047:A:G","P10636",117.926829268293,"Loss of ubiquitination at K293 (P = 0.0047); Loss of methylation at K293 (P = 0.064); Loss of glycosylation at K293 (P = 0.0907); Gain of relative solvent accessibility (P = 0.1571); Gain of disorder (P = 0.1777)",0,"K",232.765329295988,0,0,0,220.799896049896
"94",297,"A297G","MAPT",5,"","17:44061060:C:G","P10636",156.90243902439,"Loss of stability (P = 0.0889); Gain of disorder (P = 0.124); Gain of catalytic residue at A297 (P = 0.1472); Gain of methylation at K293 (P = 0.2323); Gain of ubiquitination at K293 (P = 0.3247)",1.6094379124341,"A",330.657077971234,0,0,0,428.247401247401
"95",300,"E300A","MAPT",1,"","17:44061069:A:C","P10636",332.292682926829,"Loss of solvent accessibility (P = 0.0053); Loss of catalytic residue at E300 (P = 0.0494); Loss of disorder (P = 0.0637); Loss of relative solvent accessibility (P = 0.0676); Loss of stability (P = 0.344)",0,"E",514.270249810749,1.902,0.211,0.191,249.501039501039
"96",302,"T302M","MAPT",1,"","17:44061075:C:T","P10636",244.59756097561,"Loss of disorder (P = 0.1332); Loss of glycosylation at T302 (P = 0.3172); Loss of relative solvent accessibility (P = 0.3219); Loss of phosphorylation at T302 (P = 0.4302); Loss of solvent accessibility (P = 0.5185)",0,"T",681.479939439818,1.902,0.211,0.191,301.635395010395
"97",303,"F303L","MAPT",1,"","17:44061079:T:G","P10636",117.926829268293,"Loss of stability (P = 0.1638); Gain of disorder (P = 0.1952); Gain of glycosylation at T308 (P = 0.2995); Gain of phosphorylation at T308 (P = 0.3201); Gain of catalytic residue at F303 (P = 0.4994)",0,"F",675.659348978047,1.902,0.211,0.191,291.281185031185
"98",303,"F303L","MAPT",1,"","17:44061077:T:C","P10636",117.926829268293,"Loss of stability (P = 0.1638); Gain of disorder (P = 0.1952); Gain of glycosylation at T308 (P = 0.2995); Gain of phosphorylation at T308 (P = 0.3201); Gain of catalytic residue at F303 (P = 0.4994)",0,"F",675.659348978047,1.902,0.211,0.191,291.281185031185
"99",303,"F303L","MAPT",1,"","17:44061079:T:A","P10636",117.926829268293,"Loss of stability (P = 0.1638); Gain of disorder (P = 0.1952); Gain of glycosylation at T308 (P = 0.2995); Gain of phosphorylation at T308 (P = 0.3201); Gain of catalytic residue at F303 (P = 0.4994)",0,"F",675.659348978047,1.902,0.211,0.191,291.281185031185
"100",305,"V305G","MAPT",1,"","17:44061084:T:G","P10636",166.646341463415,"Gain of disorder (P = 0.0392); Loss of stability (P = 0.0428); Loss of glycosylation at T308 (P = 0.1151); Gain of phosphorylation at T308 (P = 0.1357); Gain of relative solvent accessibility (P = 0.1571)",0,"V",546.548069644209,1.902,0.211,0.191,224.614604989605
"101",305,"V305M","MAPT",3,"","17:44061083:G:A","P10636",127.670731707317,"Loss of relative solvent accessibility (P = 0.0981); Gain of disorder (P = 0.1146); Loss of solvent accessibility (P = 0.1362); Gain of catalytic residue at H304 (P = 0.2081); Loss of glycosylation at T308 (P = 0.3019)",1.09861228866811,"V",546.548069644209,1.902,0.211,0.191,224.614604989605
"102",306,"E306A","MAPT",1,"","17:44061087:A:C","P10636",186.134146341463,"Loss of solvent accessibility (P = 0.0721); Loss of disorder (P = 0.0786); Loss of catalytic residue at E306 (P = 0.1199); Loss of glycosylation at T308 (P = 0.2872); Loss of phosphorylation at T308 (P = 0.3153)",0,"E",691.004542013626,1.902,0.211,0.191,111.626559251559
"103",309,"P309S","MAPT",1,"","17:44061095:C:T","P10636",127.670731707317,"Gain of glycosylation at P309 (P = 0.0648); Loss of catalytic residue at P309 (P = 0.1718); Loss of phosphorylation at T308 (P = 0.1943); Loss of stability (P = 0.1969); Loss of methylation at K313 (P = 0.2208)",0,"P",358.17259651779,0,0,0,240.418399168399
"104",311,"V311M","MAPT",4,"","17:44061101:G:A","P10636",20.4878048780488,"Gain of disorder (P = 0.2525); Gain of ubiquitination at K313 (P = 0.2682); Gain of glycosylation at K313 (P = 0.2797); Gain of methylation at K313 (P = 0.319); Loss of phosphorylation at T308 (P = 0.3485)",1.38629436111989,"V",270.334595003785,0,0,0,477.293659043659
"105",312,"Q312P","MAPT",1,"","17:44061105:A:C","P10636",176.390243902439,"Gain of glycosylation at Q312 (P = 0.0427); Gain of catalytic residue at N310 (P = 0.1273); Gain of phosphorylation at T308 (P = 0.1786); Gain of disorder (P = 0.2573); Gain of ubiquitination at K313 (P = 0.2754)",0,"Q",288.325510976533,0,0,0,384.469074844075
"106",313,"K313N","MAPT",3,"","17:44061109:G:C","P10636",166.646341463415,"Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of solvent accessibility (P = 0.0371); Loss of glycosylation at K313 (P = 0.1426); Loss of phosphorylation at S318 (P = 0.1733)",1.09861228866811,"K",186.729750189251,0,0,0,423.887733887734
"107",313,"K313N","MAPT",3,"","17:44061109:G:T","P10636",166.646341463415,"Loss of ubiquitination at K313 (P = 0.0059); Loss of methylation at K313 (P = 0.007); Loss of solvent accessibility (P = 0.0371); Loss of glycosylation at K313 (P = 0.1426); Loss of phosphorylation at S318 (P = 0.1733)",1.09861228866811,"K",186.729750189251,0,0,0,423.887733887734
"108",316,"A316G","MAPT",2,"","17:44061117:C:G","P10636",59.4634146341463,"Gain of relative solvent accessibility (P = 0.09); Loss of stability (P = 0.1789); Gain of phosphorylation at S318 (P = 0.2102); Gain of ubiquitination at K313 (P = 0.2182); Gain of methylation at K313 (P = 0.2982)",0.693147180559945,"A",87.779712339137,0,0,0,379.746101871102
"109",316,"A316V","MAPT",2,"","17:44061117:C:T","P10636",39.9756097560976,"Loss of ubiquitination at K313 (P = 0.0756); Loss of phosphorylation at S318 (P = 0.1905); Gain of catalytic residue at E319 (P = 0.2031); Gain of methylation at K313 (P = 0.2915); Loss of disorder (P = 0.3313)",0.693147180559945,"A",87.779712339137,0,0,0,379.746101871102
"110",325,"A325T","MAPT",1,"","17:44061143:G:A","P10636",59.4634146341463,"Gain of glycosylation at A325 (P = 0.0153); Gain of phosphorylation at A325 (P = 0.0449); Gain of solvent accessibility (P = 0.28); Loss of methylation at R324 (P = 0.3711); Loss of stability (P = 0.4356)",0,"A",393.625283875852,0,0,0,302.906964656965
"111",326,"A326T","MAPT",1,"","17:44061146:G:A","P10636",88.6951219512195,"Gain of phosphorylation at A326 (P = 0.0164); Gain of glycosylation at A326 (P = 0.0334); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.1986); Loss of stability (P = 0.2236)",0,"A",445.48145344436,0,0,0,456.040280665281
"112",331,"P331S","MAPT",1,"","17:44061161:C:T","P10636",137.414634146341,"Gain of glycosylation at P331 (P = 0.0182); Gain of phosphorylation at P331 (P = 0.0226); Loss of relative solvent accessibility (P = 0.107); Loss of solvent accessibility (P = 0.1279); Gain of catalytic residue at E333 (P = 0.4554)",0,"P",312.666161998486,0,0,0,358.492723492723
"113",334,"G334E","MAPT",7,"","17:44061171:G:A","P10636",117.926829268293,"Gain of glycosylation at P335 (P = 0.1276); Loss of catalytic residue at G334 (P = 0.1655); Gain of solvent accessibility (P = 0.2192); Loss of methylation at R338 (P = 0.2854); Gain of stability (P = 0.8311)",1.94591014905531,"G",159.214231642695,0,0,0,362.12577962578
"114",335,"P335A","MAPT",1,"","17:44061173:C:G","P10636",69.2073170731707,"Loss of catalytic residue at P335 (P = 0.1115); Loss of glycosylation at P335 (P = 0.1528); Gain of methylation at R338 (P = 0.1585); Loss of solvent accessibility (P = 0.5743); Gain of MoRF binding (P = 0.7901)",0,"P",168.738834216503,0,0,0,673.47869022869
"115",335,"P335Q","MAPT",1,"","17:44061174:C:A","P10636",78.9512195121951,"Loss of catalytic residue at P335 (P = 0.0747); Loss of glycosylation at P335 (P = 0.1528); Loss of relative solvent accessibility (P = 0.1807); Loss of methylation at R338 (P = 0.2412); Loss of solvent accessibility (P = 0.3473)",0,"P",168.738834216503,0,0,0,673.47869022869
"116",339,"G339A","MAPT",1,"","17:44061186:G:C","P10636",69.2073170731707,"Loss of catalytic residue at P335 (P = 0.0775); Loss of relative solvent accessibility (P = 0.0981); Loss of methylation at R338 (P = 0.2641); Gain of glycosylation at S341 (P = 0.3096); Loss of solvent accessibility (P = 0.3368)",0,"G",238.585919757759,0,0,0,484.378118503118
"117",346,"T346A","MAPT",2,"","17:44061206:A:G","P10636",30.2317073170732,"Loss of phosphorylation at T346 (P = 0.0093); Loss of glycosylation at T346 (P = 0.0761); Loss of methylation at K347 (P = 0.2073); Loss of ubiquitination at K347 (P = 0.4093); Loss of solvent accessibility (P = 0.4995)",0.693147180559945,"T",219.536714610144,0,0,0,331.608108108108
"118",348,"E348D","MAPT",2,"","17:44061214:G:C","P10636",30.2317073170732,"Loss of methylation at K347 (P = 0.1956); Loss of glycosylation at K347 (P = 0.1987); Loss of ubiquitination at K347 (P = 0.4033); Loss of solvent accessibility (P = 0.5485); Gain of catalytic residue at K347 (P = 0.6101)",0.693147180559945,"E",83.0174110522332,0,0,0,361.580821205821
"119",348,"E348D","MAPT",2,"","17:44061214:G:T","P10636",30.2317073170732,"Loss of methylation at K347 (P = 0.1956); Loss of glycosylation at K347 (P = 0.1987); Loss of ubiquitination at K347 (P = 0.4033); Loss of solvent accessibility (P = 0.5485); Gain of catalytic residue at K347 (P = 0.6101)",0.693147180559945,"E",83.0174110522332,0,0,0,361.580821205821
"120",355,"S355C","MAPT",3,"","17:44061234:C:G","P10636",108.182926829268,"Loss of phosphorylation at S355 (P = 0.0069); Gain of catalytic residue at P354 (P = 0.0073); Loss of glycosylation at S355 (P = 0.0363); Loss of relative solvent accessibility (P = 0.0676); Loss of solvent accessibility (P = 0.086)",1.09861228866811,"S",167.151400454201,0,0,0,254.768970893971
"121",355,"S355F","MAPT",3,"","17:44061234:C:T","P10636",156.90243902439,"Loss of phosphorylation at S355 (P = 0.0069); Loss of relative solvent accessibility (P = 0.0186); Loss of glycosylation at S355 (P = 0.0363); Loss of solvent accessibility (P = 0.045); Gain of catalytic residue at S355 (P = 0.0645)",1.09861228866811,"S",167.151400454201,0,0,0,254.768970893971
"122",355,"S355P","MAPT",1,"","17:44061233:T:C","P10636",127.670731707317,"Loss of phosphorylation at S355 (P = 0.0069); Gain of catalytic residue at P354 (P = 0.0168); Gain of sheet (P = 0.0507); Loss of loop (P = 0.0603); Gain of glycosylation at S355 (P = 0.1106)",0,"S",167.151400454201,0,0,0,254.768970893971
"123",357,"K357E","MAPT",2,"","17:44061239:A:G","P10636",127.670731707317,"Loss of ubiquitination at K357 (P = 0.0043); Loss of methylation at K357 (P = 0.0087); Loss of glycosylation at K357 (P = 0.0326); Loss of MoRF binding (P = 0.0726); Gain of helix (P = 0.0893)",0.693147180559945,"K",185.671461014383,0,0,0,154.133316008316
"124",363,"P363L","MAPT",1,"","17:44061258:C:T","P10636",127.670731707317,"Loss of methylation at K366 (P = 0.0548); Gain of MoRF binding (P = 0.0551); Loss of glycosylation at P363 (P = 0.098); Loss of ubiquitination at K366 (P = 0.1062); Gain of catalytic residue at K366 (P = 0.4592)",0,"P",326.953065859198,0,0,0,419.346413721414
"125",363,"P363S","MAPT",1,"","17:44061257:C:T","P10636",98.4390243902439,"Gain of phosphorylation at P363 (P = 0.0081); Gain of MoRF binding (P = 0.0477); Loss of methylation at K366 (P = 0.0696); Loss of ubiquitination at K366 (P = 0.1216); Loss of stability (P = 0.286)",0,"P",326.953065859198,0,0,0,419.346413721414
"126",364,"R364P","MAPT",4,"","17:44061261:G:C","P10636",195.878048780488,"Loss of MoRF binding (P = 0.0107); Gain of glycosylation at R364 (P = 0.0113); Gain of catalytic residue at P363 (P = 0.018); Loss of methylation at R364 (P = 0.0297); Gain of ubiquitination at K366 (P = 0.1204)",1.38629436111989,"R",371.930355791067,0,0,0,239.873440748441
"127",364,"R364Q","MAPT",4,"","17:44061261:G:A","P10636",156.90243902439,"Loss of methylation at R364 (P = 0.0297); Loss of MoRF binding (P = 0.0491); Gain of ubiquitination at K366 (P = 0.0719); Gain of relative solvent accessibility (P = 0.1571); Gain of glycosylation at K366 (P = 0.2002)",1.38629436111989,"R",371.930355791067,0,0,0,239.873440748441
"128",364,"R364W","MAPT",1,"","17:44061260:C:T","P10636",176.390243902439,"Loss of solvent accessibility (P = 0.0087); Gain of catalytic residue at P367 (P = 0.0259); Loss of methylation at R364 (P = 0.0297); Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K366 (P = 0.1062)",0,"R",371.930355791067,0,0,0,239.873440748441
"129",365,"G365E","MAPT",3,"","17:44061264:G:A","P10636",117.926829268293,"Loss of MoRF binding (P = 0.0432); Loss of methylation at R364 (P = 0.0491); Gain of solvent accessibility (P = 0.0789); Gain of glycosylation at P363 (P = 0.086); Loss of ubiquitination at K366 (P = 0.093)",1.09861228866811,"G",328.540499621499,0,0,0,256.767151767152
"130",368,"V368I","MAPT",2,"","17:44061272:G:A","P10636",59.4634146341463,"Loss of methylation at R364 (P = 0.1197); Gain of ubiquitination at K366 (P = 0.1204); Loss of MoRF binding (P = 0.1294); Gain of glycosylation at K366 (P = 0.1934); Gain of stability (P = 0.2833)",0.693147180559945,"V",334.890234670704,0,0,0,331.789760914761
"131",370,"R370Q","MAPT",1,"","17:44061279:G:A","P10636",195.878048780488,"Loss of MoRF binding (P = 0.0393); Gain of methylation at K366 (P = 0.0916); Loss of catalytic residue at R370 (P = 0.0977); Loss of ubiquitination at K366 (P = 0.1216); Gain of relative solvent accessibility (P = 0.1571)",0,"R",432.252838758516,0,0,0,72.9345114345114
"132",372,"P372A","MAPT",2,"","17:44061284:C:G","P10636",147.158536585366,"Loss of methylation at K375 (P = 0.1039); Loss of solvent accessibility (P = 0.1322); Loss of relative solvent accessibility (P = 0.1807); Loss of ubiquitination at K375 (P = 0.1881); Gain of MoRF binding (P = 0.2258)",0.693147180559945,"P",441.777441332324,0,0,0,56.404106029106
"133",378,"M378L","MAPT",1,"","17:44064411:A:T","P10636",117.926829268293,"Loss of methylation at K383 (P = 0.0863); Loss of ubiquitination at K383 (P = 0.1741); Gain of glycosylation at S382 (P = 0.2948); Loss of catalytic residue at M378 (P = 0.3255); Loss of MoRF binding (P = 0.3909)",0,"M",396.800151400454,0,0,0,316.349272349272
"134",378,"M378L","MAPT",1,"","17:44064411:A:C","P10636",117.926829268293,"Loss of methylation at K383 (P = 0.0863); Loss of ubiquitination at K383 (P = 0.1741); Gain of glycosylation at S382 (P = 0.2948); Loss of catalytic residue at M378 (P = 0.3255); Loss of MoRF binding (P = 0.3909)",0,"M",396.800151400454,0,0,0,316.349272349272
"135",379,"V379D","MAPT",2,"","17:44064415:T:A","P10636",195.878048780488,"Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0314); Loss of stability (P = 0.0332); Gain of ubiquitination at K383 (P = 0.0369); Loss of methylation at K383 (P = 0.0998)",0.693147180559945,"V",367.697199091597,0,0,0,280.563669438669
"136",381,"K381E","MAPT",1,"","17:44064420:A:G","P10636",225.109756097561,"Loss of ubiquitination at K381 (P = 0.0063); Loss of MoRF binding (P = 0.0135); Loss of catalytic residue at K381 (P = 0.0276); Loss of methylation at K383 (P = 0.1146); Gain of relative solvent accessibility (P = 0.1571)",0,"K",312.666161998486,0,0,0,100.727390852391
"137",385,"G385R","MAPT",4,"","17:44064432:G:C","P10636",147.158536585366,"Loss of ubiquitination at K381 (P = 0.0272); Gain of methylation at K383 (P = 0.1139); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S382 (P = 0.2266); Gain of MoRF binding (P = 0.2471)",1.38629436111989,"G",36.9818319454959,0,0,0,143.052494802495
"138",385,"G385R","MAPT",4,"","17:44064432:G:A","P10636",147.158536585366,"Loss of ubiquitination at K381 (P = 0.0272); Gain of methylation at K383 (P = 0.1139); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at S382 (P = 0.2266); Gain of MoRF binding (P = 0.2471)",1.38629436111989,"G",36.9818319454959,0,0,0,143.052494802495
"139",389,"D389N","MAPT",1,"","17:44064444:G:A","P10636",127.670731707317,"Loss of ubiquitination at K394 (P = 0.0365); Loss of solvent accessibility (P = 0.0387); Gain of methylation at K391 (P = 0.0582); Loss of relative solvent accessibility (P = 0.0676); Loss of stability (P = 0.2324)",0,"D",18.9909159727479,0,0,0,320.345634095634
"140",394,"K394R","MAPT",1,"","17:44064460:A:G","P10636",98.4390243902439,"Loss of ubiquitination at K394 (P = 0.0167); Loss of methylation at K394 (P = 0.0424); Loss of solvent accessibility (P = 0.1115); Loss of relative solvent accessibility (P = 0.1807); Loss of glycosylation at T397 (P = 0.2534)",0,"K",77.1968205904618,0,0,0,64.9417879417879
"141",395,"T395I","MAPT",2,"","17:44067245:C:T","P10636",78.9512195121951,"Loss of phosphorylation at T395 (P = 0.0096); Gain of methylation at K394 (P = 0.0537); Loss of ubiquitination at K394 (P = 0.0755); Loss of relative solvent accessibility (P = 0.0981); Gain of glycosylation at T397 (P = 0.1033)",0.693147180559945,"T",151.277062831188,0,0,0,145.413981288981
"142",396,"S396P","MAPT",1,"","17:44067247:T:C","P10636",117.926829268293,"Loss of phosphorylation at S396 (P = 0.0041); Gain of methylation at K394 (P = 0.0702); Loss of glycosylation at S396 (P = 0.0955); Loss of ubiquitination at K394 (P = 0.1322); Loss of MoRF binding (P = 0.2161)",0,"S",238.056775170326,0,0,0,64.0335239085239
"143",398,"R398H","MAPT",2,"","17:44067254:G:A","P10636",215.365853658537,"Loss of MoRF binding (P = 0.0388); Gain of methylation at K394 (P = 0.0497); Gain of ubiquitination at K394 (P = 0.0598); Gain of glycosylation at T395 (P = 0.0682); Loss of phosphorylation at T397 (P = 0.2119)",0.693147180559945,"R",275.096896290689,0,0,0,96.0044178794179
"144",405,"K405R","MAPT",1,"","17:44067275:A:G","P10636",244.59756097561,"Loss of methylation at K405 (P = 0.0295); Loss of ubiquitination at K405 (P = 0.0496); Gain of MoRF binding (P = 0.0899); Loss of glycosylation at P408 (P = 0.2929); Loss of solvent accessibility (P = 0.2953)",0,"K",403.679031037093,0,0,0,337.057692307692
"145",406,"N406S","MAPT",1,"","17:44067278:A:G","P10636",254.341463414634,"Gain of phosphorylation at N406 (P = 0.0104); Gain of glycosylation at N406 (P = 0.0257); Loss of methylation at K405 (P = 0.1314); Loss of MoRF binding (P = 0.1439); Gain of relative solvent accessibility (P = 0.1571)",0,"N",403.679031037093,0,0,0,685.649428274428
"146",408,"P408T","MAPT",3,"","17:44067283:C:A","P10636",186.134146341463,"Loss of catalytic residue at P408 (P = 0.0197); Gain of phosphorylation at P408 (P = 0.0275); Loss of stability (P = 0.0537); Gain of MoRF binding (P = 0.0566); Loss of glycosylation at P408 (P = 0.1022)",1.09861228866811,"P",389.392127176382,0,0,0,214.805353430353
"147",412,"P412S","MAPT",1,"","17:44067295:C:T","P10636",117.926829268293,"Gain of phosphorylation at P412 (P = 0.021); Gain of MoRF binding (P = 0.0585); Loss of glycosylation at K413 (P = 0.1057); Loss of methylation at K413 (P = 0.1391); Loss of stability (P = 0.1842)",0,"P",348.118849356548,0,0,0,139.964397089397
"148",416,"T416A","MAPT",1,"","17:44067307:A:G","P10636",195.878048780488,"Loss of phosphorylation at T416 (P = 0.0059); Loss of glycosylation at T416 (P = 0.0153); Loss of solvent accessibility (P = 0.1177); Loss of methylation at K413 (P = 0.1713); Loss of relative solvent accessibility (P = 0.1807)",0,"T",186.200605601817,0,0,0,164.12422037422
"149",424,"I424S","MAPT",1,"","17:44067332:T:G","P10636",234.853658536585,"Gain of phosphorylation at I424 (P = 0.0068); Gain of glycosylation at I424 (P = 0.0183); Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0854); Loss of stability (P = 0.0866)",0,"I",394.683573050719,0,0,0,128.883575883576
"150",424,"I424V","MAPT",1,"","17:44067331:A:G","P10636",195.878048780488,"Gain of relative solvent accessibility (P = 0.0249); Gain of solvent accessibility (P = 0.0674); Gain of glycosylation at S419 (P = 0.1305); Gain of phosphorylation at S427 (P = 0.5581); Loss of sheet (P = 0.6423)",0,"I",394.683573050719,0,0,0,128.883575883576
"151",428,"S428R","MAPT",1,"","17:44067345:C:G","P10636",225.109756097561,"Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0314); Gain of solvent accessibility (P = 0.3304); Loss of stability (P = 0.5068)",0,"S",615.336866010598,0.502,0,0.231,77.6574844074844
"152",428,"S428R","MAPT",1,"","17:44067343:A:C","P10636",225.109756097561,"Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0314); Gain of solvent accessibility (P = 0.3304); Loss of stability (P = 0.5068)",0,"S",615.336866010598,0.502,0,0.231,77.6574844074844
"153",428,"S428R","MAPT",1,"","17:44067345:C:A","P10636",225.109756097561,"Loss of glycosylation at S428 (P = 0.0088); Loss of phosphorylation at S428 (P = 0.0119); Gain of catalytic residue at S428 (P = 0.0314); Gain of solvent accessibility (P = 0.3304); Loss of stability (P = 0.5068)",0,"S",615.336866010598,0.502,0,0.231,77.6574844074844
"154",434,"E434Q","MAPT",1,"","17:44067361:G:C","P10636",283.573170731707,"Loss of catalytic residue at E434 (P = 0.046); Loss of solvent accessibility (P = 0.0721); Loss of glycosylation at P433 (P = 0.0831); Loss of relative solvent accessibility (P = 0.1807); Gain of MoRF binding (P = 0.431)",0,"E",420.611657834973,0,0,0,234.060550935551
"155",437,"S437F","MAPT",1,"","17:44067371:C:T","P10636",127.670731707317,"Loss of phosphorylation at S437 (P = 0.0065); Loss of glycosylation at S437 (P = 0.0215); Gain of catalytic residue at S437 (P = 0.1031); Gain of solvent accessibility (P = 0.1376); Loss of MoRF binding (P = 0.2549)",0,"S",449.185465556397,0,0,0,78.7474012474012
"156",439,"P439S","MAPT",1,"","17:44067376:C:T","P10636",127.670731707317,"Gain of phosphorylation at P439 (P = 0.0096); Gain of MoRF binding (P = 0.0695); Loss of glycosylation at S437 (P = 0.1174); Loss of stability (P = 0.1319); Loss of methylation at K440 (P = 0.1424)",0,"P",407.912187736563,0,0,0,91.8264033264033
"157",442,"V442I","MAPT",1,"","17:44067385:G:A","P10636",88.6951219512195,"Gain of MoRF binding (P = 0.1396); Loss of glycosylation at S437 (P = 0.1701); Loss of phosphorylation at T446 (P = 0.2244); Gain of methylation at K440 (P = 0.2628); Gain of catalytic residue at S444 (P = 0.2881)",0,"V",562.951551854655,0.756,0.108,0.088,248.592775467775
"158",461,"G461E","MAPT",7,"","17:44068827:G:A","P10636",205.621951219512,"Gain of solvent accessibility (P = 0.024); Gain of ubiquitination at K460 (P = 0.0415); Loss of MoRF binding (P = 0.082); Gain of methylation at K465 (P = 0.2458); Loss of glycosylation at K460 (P = 0.246)",1.94591014905531,"G",251.814534443603,0,0,0,346.685291060291
"159",469,"A469S","MAPT",163,"","17:44068850:G:T","P10636",156.90243902439,"Gain of phosphorylation at A469 (P = 0.0153); Gain of glycosylation at A469 (P = 0.0162); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K467 (P = 0.1278); Gain of solvent accessibility (P = 0.1319)",5.09375020080676,"A",345.473126419379,0,0,0,314.169438669439
"160",476,"P476L","MAPT",1,"","17:44068872:C:T","P10636",273.829268292683,"Loss of glycosylation at P476 (P = 0.0375); Gain of MoRF binding (P = 0.0653); Loss of methylation at K480 (P = 0.0666); Gain of ubiquitination at K480 (P = 0.0972); Loss of relative solvent accessibility (P = 0.0981)",0,"P",200.487509462528,0,0,0,423.524428274428
"161",482,"Q482P","MAPT",4,"","17:44068890:A:C","P10636",176.390243902439,"Gain of glycosylation at Q482 (P = 0.0342); Loss of MoRF binding (P = 0.0585); Gain of methylation at R487 (P = 0.1389); Loss of ubiquitination at K480 (P = 0.1423); Gain of catalytic residue at G481 (P = 0.1627)",1.38629436111989,"Q",129.052990158971,0,0,0,478.928534303534
"162",482,"Q482R","MAPT",4,"","17:44068890:A:G","P10636",186.134146341463,"Gain of methylation at Q482 (P = 0.0094); Gain of MoRF binding (P = 0.0526); Gain of catalytic residue at Q482 (P = 0.0953); Loss of ubiquitination at K480 (P = 0.1091); Loss of glycosylation at K480 (P = 0.1466)",1.38629436111989,"Q",129.052990158971,0,0,0,478.928534303534
"163",483,"A483V","MAPT",1,"","17:44068893:C:T","P10636",186.134146341463,"Loss of relative solvent accessibility (P = 0.0981); Loss of ubiquitination at K480 (P = 0.1264); Gain of MoRF binding (P = 0.1382); Gain of methylation at K480 (P = 0.1536); Loss of phosphorylation at T486 (P = 0.1705)",0,"A",232.765329295988,0,0,0,279.655405405405
"164",485,"A485T","MAPT",1,"","17:44068898:G:A","P10636",244.59756097561,"Gain of glycosylation at A485 (P = 0.0067); Gain of phosphorylation at A485 (P = 0.0596); Gain of catalytic residue at A485 (P = 0.0825); Gain of methylation at K480 (P = 0.0962); Loss of MoRF binding (P = 0.1086)",0,"A",299.966691900076,0,0,0,182.834459459459
"165",487,"R487K","MAPT",1,"","17:44068905:G:A","P10636",273.829268292683,"Gain of methylation at R487 (P = 0.021); Gain of ubiquitination at R487 (P = 0.03); Loss of MoRF binding (P = 0.0738); Gain of glycosylation at R487 (P = 0.0973); Loss of catalytic residue at R487 (P = 0.1478)",0,"R",317.957607872824,0,0,0,168.120582120582
"166",492,"T492P","MAPT",2,"","17:44068919:A:C","P10636",205.621951219512,"Loss of phosphorylation at T492 (P = 0.0034); Gain of catalytic residue at T492 (P = 0.0055); Loss of MoRF binding (P = 0.0688); Gain of glycosylation at P493 (P = 0.0846); Gain of ubiquitination at K491 (P = 0.115)",0.693147180559945,"T",356.056018168054,0,0,0,134.151507276507
"167",494,"P494L","MAPT",1,"","17:44068926:C:T","P10636",176.390243902439,"Loss of glycosylation at P494 (P = 0.0078); Loss of catalytic residue at P493 (P = 0.0219); Gain of stability (P = 0.0311); Loss of ubiquitination at K491 (P = 0.0587); Gain of MoRF binding (P = 0.0744)",0,"P",304.199848599546,0,0,0,272.934251559252
"168",503,"G503S","MAPT",1,"","17:44068952:G:A","P10636",225.109756097561,"Gain of phosphorylation at G503 (P = 7e-04); Gain of glycosylation at G503 (P = 0.0113); Gain of solvent accessibility (P = 0.1683); Loss of ubiquitination at K507 (P = 0.321); Gain of methylation at K507 (P = 0.4965)",0,"G",240.173353520061,0,0,0,81.1088877338877
"169",511,"R511C","MAPT",1,"","17:44073788:C:T","P10636",234.853658536585,"Gain of glycosylation at S508 (P = 0.0758); Loss of MoRF binding (P = 0.1399); Gain of catalytic residue at G513 (P = 0.1731); Loss of solvent accessibility (P = 0.2668); Loss of ubiquitination at K507 (P = 0.2936)",0,"R",232.236184708554,0,0,0,36.7856029106029
"170",521,"G521S","MAPT",1,"","17:44073818:G:A","P10636",176.390243902439,"Gain of phosphorylation at G521 (P = 4e-04); Gain of glycosylation at G521 (P = 0.0055); Loss of catalytic residue at P517 (P = 0.0852); Loss of methylation at R526 (P = 0.1152); Gain of solvent accessibility (P = 0.1683)",0,"G",258.164269492808,0,0,0,132.153326403326
"171",528,"R528C","MAPT",3,"","17:44073839:C:T","P10636",215.365853658537,"Loss of methylation at R528 (P = 0.0265); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0829); Gain of glycosylation at P523 (P = 0.1117); Loss of catalytic residue at S527 (P = 0.2345)",1.09861228866811,"R",316.370174110522,0,0,0,137.057952182952
"172",528,"R528H","MAPT",1,"","17:44073840:G:A","P10636",186.134146341463,"Loss of methylation at R528 (P = 0.0265); Gain of relative solvent accessibility (P = 0.0479); Loss of MoRF binding (P = 0.0967); Gain of solvent accessibility (P = 0.0971); Gain of glycosylation at S531 (P = 0.1424)",0,"R",316.370174110522,0,0,0,137.057952182952
"173",529,"T529N","MAPT",1,"","17:44073843:C:A","P10636",205.621951219512,"Loss of phosphorylation at T529 (P = 7e-04); Loss of glycosylation at S527 (P = 0.1013); Loss of methylation at R526 (P = 0.1429); Gain of MoRF binding (P = 0.2209); Loss of stability (P = 0.3382)",0,"T",324.836487509463,0,0,0,78.2024428274428
"174",534,"T534I","MAPT",3,"","17:44073858:C:T","P10636",117.926829268293,"Loss of glycosylation at T534 (P = 0.0065); Loss of phosphorylation at T534 (P = 0.0083); Gain of catalytic residue at P536 (P = 0.064); Loss of MoRF binding (P = 0.1365); Loss of methylation at R538 (P = 0.4691)",1.09861228866811,"T",330.657077971234,0,0,0,86.1951663201663
"175",538,"R538Q","MAPT",1,"","17:44073870:G:A","P10636",205.621951219512,"Gain of relative solvent accessibility (P = 0.0166); Gain of solvent accessibility (P = 0.0171); Loss of MoRF binding (P = 0.0174); Gain of glycosylation at K541 (P = 0.1149); Gain of ubiquitination at K542 (P = 0.1317)",0,"R",272.980317940954,0,0,0,155.949844074844
"176",556,"A556S","MAPT",93,"","17:44073923:G:T","P10636",127.670731707317,"Gain of phosphorylation at A556 (P = 0.0067); Loss of helix (P = 0.0376); Gain of glycosylation at A556 (P = 0.0492); Gain of loop (P = 0.0851); Gain of methylation at K551 (P = 0.0891)",4.53259949315326,"A",276.68433005299,0,0,0,232.06237006237
"177",558,"S558G","MAPT",1,"","17:44073929:A:G","P10636",166.646341463415,"Loss of phosphorylation at S558 (P = 0.0113); Gain of relative solvent accessibility (P = 0.0275); Gain of methylation at R559 (P = 0.0415); Loss of glycosylation at S558 (P = 0.0419); Gain of helix (P = 0.0854)",0,"S",326.423921271764,0,0,0,157.948024948025
"178",563,"A563T","MAPT",24,"","17:44073944:G:A","P10636",234.853658536585,"Gain of glycosylation at A563 (P = 0.0023); Gain of phosphorylation at A563 (P = 0.0254); Loss of MoRF binding (P = 0.1123); Loss of stability (P = 0.119); Loss of methylation at R559 (P = 0.2173)",3.17805383034795,"A",489.400454201363,0.013,0,-0.007,143.597453222453
"179",565,"V565L","MAPT",9,"","17:44073950:G:C","P10636",293.317073170732,"Loss of MoRF binding (P = 0.0915); Gain of glycosylation at P566 (P = 0.1073); Gain of catalytic residue at V565 (P = 0.1945); Loss of phosphorylation at T562 (P = 0.3858); Loss of helix (P = 0.3949)",2.19722457733622,"V",541.256623769871,0.111,0,0.091,117.439449064449
"180",565,"V565L","MAPT",9,"","17:44073950:G:T","P10636",293.317073170732,"Loss of MoRF binding (P = 0.0915); Gain of glycosylation at P566 (P = 0.1073); Gain of catalytic residue at V565 (P = 0.1945); Loss of phosphorylation at T562 (P = 0.3858); Loss of helix (P = 0.3949)",2.19722457733622,"V",541.256623769871,0.111,0,0.091,117.439449064449
"181",568,"P568A","MAPT",1,"","17:44073959:C:G","P10636",390.756097560976,"Gain of MoRF binding (P = 0.0381); Gain of helix (P = 0.0425); Loss of loop (P = 0.0512); Loss of methylation at K571 (P = 0.0693); Loss of glycosylation at P568 (P = 0.1265)",0,"P",511.095382286147,0,0,0,49.3196465696466
"182",573,"V573I","MAPT",1,"","17:44073974:G:A","P10636",614.865853658537,"Loss of methylation at K574 (P = 0.0641); Loss of ubiquitination at K574 (P = 0.0724); Loss of MoRF binding (P = 0.1415); Loss of glycosylation at S575 (P = 0.1441); Gain of helix (P = 0.1736)",0,"V",382.513247539743,0,0,0,97.2759875259875
"183",574,"K574T","MAPT",0.1,"P","17:44073978:A:C","P10636",517.426829268293,"Loss of methylation at K574 (P = 0.0097); Loss of ubiquitination at K574 (P = 0.0107); Gain of glycosylation at K574 (P = 0.0461); Loss of MoRF binding (P = 0.0659); Loss of helix (P = 0.079)",-2.30258509299405,"K",384.629825889478,0,0,0,301.272089397089
"184",583,"L583V","MAPT",0.1,"P","17:44074004:C:G","P10636",556.40243902439,"Gain of methylation at K584 (P = 0.0382); Gain of MoRF binding (P = 0.0901); Loss of stability (P = 0.104); Gain of ubiquitination at K584 (P = 0.123); Loss of catalytic residue at L583 (P = 0.1757)",-2.30258509299405,"L",185.671461014383,0,0,0,81.2905405405405
"185",589,"G589V","MAPT",0.1,"P","17:44074023:G:T","P10636",673.329268292683,"Loss of ubiquitination at K591 (P = 0.0598); Gain of MoRF binding (P = 0.1002); Gain of methylation at K584 (P = 0.1046); Loss of glycosylation at K591 (P = 0.2578); Loss of catalytic residue at G588 (P = 0.2808)",-2.30258509299405,"G",306.316426949281,0,0,0,58.7655925155925
"186",596,"N596K","MAPT",0.1,"P","17:44087690:T:G","P10636",683.073170731707,"Gain of catalytic residue at N596 (P = 0.0171); Loss of ubiquitination at K591 (P = 0.0211); Gain of MoRF binding (P = 0.034); Gain of solvent accessibility (P = 0.0354); Gain of relative solvent accessibility (P = 0.0479)",-2.30258509299405,"N",533.319454958365,0.25,0,0.105,39.6920478170478
"187",596,"N596K","MAPT",0.1,"P","17:44087690:T:A","P10636",683.073170731707,"Gain of catalytic residue at N596 (P = 0.0171); Loss of ubiquitination at K591 (P = 0.0211); Gain of MoRF binding (P = 0.034); Gain of solvent accessibility (P = 0.0354); Gain of relative solvent accessibility (P = 0.0479)",-2.30258509299405,"N",533.319454958365,0.25,0,0.105,39.6920478170478
"188",597,"K597R","MAPT",1,"","17:44087692:A:G","P10636",468.707317073171,"Gain of MoRF binding (P = 0.0704); Loss of ubiquitination at K597 (P = 0.0982); Loss of disorder (P = 0.1073); Gain of methylation at K598 (P = 0.2086); Loss of sheet (P = 0.302)",0,"K",564.009841029523,0.25,0,0.105,21.7084199584199
"189",618,"P618L","MAPT",0.1,"P","17:44087755:C:T","P10636",800,"Gain of catalytic residue at P618 (P = 0.024); Loss of disorder (P = 0.0325); Loss of ubiquitination at K615 (P = 0.0709); Gain of sheet (P = 0.1208); Gain of MoRF binding (P = 0.1587)",-2.30258509299405,"P",469.822104466313,0,0,0,48.5930353430353
"190",618,"P618S","MAPT",0.1,"P","17:44087754:C:T","P10636",770.768292682927,"Gain of catalytic residue at P618 (P = 0.0465); Gain of sheet (P = 0.0477); Gain of relative solvent accessibility (P = 0.09); Gain of ubiquitination at K615 (P = 0.0918); Gain of MoRF binding (P = 0.1007)",-2.30258509299405,"P",469.822104466313,0,0,0,48.5930353430353
"191",620,"G620V","MAPT",0.1,"P","17:44087761:G:T","P10636",761.024390243902,"Loss of ubiquitination at K615 (P = 0.0505); Loss of disorder (P = 0.0584); Gain of sheet (P = 0.1208); Loss of relative solvent accessibility (P = 0.3219); Gain of MoRF binding (P = 0.3398)",-2.30258509299405,"G",472.996971990916,0,0,0,9.90098752598751
"192",621,"G621S","MAPT",2,"","17:44087763:G:A","P10636",790.256097560976,"Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at G621 (P = 0.0762); Gain of disorder (P = 0.0936); Gain of solvent accessibility (P = 0.11); Loss of sheet (P = 0.1398)",0.693147180559945,"G",594.700227100681,2.478,0.31,0.29,32.4259355509355
"193",622,"S622N","MAPT",0.1,"P","17:44087767:G:A","P10636",585.634146341463,"Gain of relative solvent accessibility (P = 0.0479); Gain of solvent accessibility (P = 0.0766); Loss of disorder (P = 0.1047); Gain of catalytic residue at S622 (P = 0.189); Loss of sheet (P = 0.1907)",-2.30258509299405,"S",700,2.478,0.31,0.29,23.1616424116424
"194",634,"K634M","MAPT",0.1,"P","17:44091643:A:T","P10636",663.585365853658,"Gain of catalytic residue at V630 (P = 0.0127); Loss of ubiquitination at K634 (P = 0.0155); Loss of disorder (P = 0.0289); Gain of glycosylation at S637 (P = 0.086); Loss of MoRF binding (P = 0.0944)",-2.30258509299405,"K",512.153671461014,0.093,0,0.027,95.6411122661122
"195",637,"S637F","MAPT",0.1,"P","17:44091652:C:T","P10636",702.560975609756,"Loss of disorder (P = 0.0034); Loss of ubiquitination at K634 (P = 0.0369); Gain of sheet (P = 0.0477); Loss of glycosylation at S637 (P = 0.08); Loss of loop (P = 0.0804)",-2.30258509299405,"S",566.126419379258,0.158,0,0.138,9.90098752598751
"196",654,"V654M","MAPT",0.1,"P","17:44095995:G:A","P10636",722.048780487805,"Gain of ubiquitination at K657 (P = 0.14); Loss of sheet (P = 0.1501); Gain of phosphorylation at S658 (P = 0.2252); Gain of relative solvent accessibility (P = 0.281); Gain of catalytic residue at V654 (P = 0.3517)",-2.30258509299405,"V",299.437547312642,0,0,0,13.170738045738
"197",659,"E659V","MAPT",0.1,"P","17:44096011:A:T","P10636",673.329268292683,"Gain of MoRF binding (P = 0.0249); Loss of ubiquitination at K664 (P = 0.0334); Gain of sheet (P = 0.039); Loss of disorder (P = 0.0612); Loss of catalytic residue at E659 (P = 0.0612)",-2.30258509299405,"E",424.31566994701,0,0,0,35.8773388773389
"198",669,"S669L","MAPT",0.1,"P","17:44096041:C:T","P10636",644.09756097561,"Loss of disorder (P = 0.0143); Loss of glycosylation at S669 (P = 0.0194); Loss of phosphorylation at S669 (P = 0.0387); Gain of relative solvent accessibility (P = 0.0479); Gain of catalytic residue at S669 (P = 0.06)",-2.30258509299405,"S",372.988644965935,0,0,0,22.2533783783784
"199",669,"S669P","MAPT",2,"","17:44096040:T:C","P10636",595.378048780488,"Gain of relative solvent accessibility (P = 0.0082); Loss of glycosylation at S669 (P = 0.0242); Gain of solvent accessibility (P = 0.0256); Loss of phosphorylation at S669 (P = 0.0387); Loss of stability (P = 0.0797)",0.693147180559945,"S",372.988644965935,0,0,0,22.2533783783784
"200",671,"I671T","MAPT",2,"","17:44096047:T:C","P10636",692.817073170732,"Gain of relative solvent accessibility (P = 0.0082); Gain of solvent accessibility (P = 0.0202); Loss of stability (P = 0.0218); Loss of helix (P = 0.0376); Gain of disorder (P = 0.0436)",0.693147180559945,"I",354.997728993187,0,0,0,38.9654365904366
"201",675,"D675G","MAPT",1,"","17:44096059:A:G","P10636",653.841463414634,"Loss of catalytic residue at D675 (P = 0.0051); Gain of MoRF binding (P = 0.0462); Gain of sheet (P = 0.0827); Loss of stability (P = 0.1052); Loss of ubiquitination at K670 (P = 0.1139)",0,"D",518.50340651022,0.19,0,0.075,101.454002079002
"202",680,"V680I","MAPT",2,"","17:44096073:G:A","P10636",585.634146341463,"Gain of catalytic residue at V680 (P = 0.1713); Gain of disorder (P = 0.2354); Loss of phosphorylation at T678 (P = 0.2621); Loss of sheet (P = 0.302); Loss of glycosylation at T678 (P = 0.3298)",0.693147180559945,"V",293.087812263437,0,0,0,81.6538461538461
"203",686,"K686I","MAPT",0.1,"P","17:44096092:A:T","P10636",595.378048780488,"Loss of disorder (P = 0.0187); Loss of methylation at K686 (P = 0.0305); Gain of ubiquitination at K687 (P = 0.0326); Gain of sheet (P = 0.039); Loss of glycosylation at K686 (P = 0.0671)",-2.30258509299405,"K",210.012112036336,0,0,0,113.443087318087
"204",696,"R696C","MAPT",1,"","17:44101346:C:T","P10636",400.5,"Loss of MoRF binding (P = 0.0209); Loss of disorder (P = 0.0354); Gain of methylation at K692 (P = 0.0439); Loss of catalytic residue at R696 (P = 0.0652); Gain of ubiquitination at K700 (P = 0.1092)",0,"R",303.141559424678,0,0,0,3.17983367983368
"205",700,"K700E","MAPT",1,"","17:44101358:A:G","P10636",303.060975609756,"Loss of ubiquitination at K700 (P = 0.0148); Loss of MoRF binding (P = 0.0302); Gain of helix (P = 0.062); Loss of loop (P = 0.1242); Loss of sheet (P = 0.1907)",0,"K",148.63133989402,0,0,0,40.418659043659
"206",702,"K702E","MAPT",1,"","17:44101364:A:G","P10636",361.524390243902,"Loss of ubiquitination at K702 (P = 0.0148); Loss of MoRF binding (P = 0.0521); Loss of helix (P = 0.079); Gain of relative solvent accessibility (P = 0.09); Gain of solvent accessibility (P = 0.1116)",0,"K",96.2460257380772,0,0,0,20.9818087318087
"207",706,"G706R","MAPT",2,"","17:44101376:G:C","P10636",527.170731707317,"Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)",0.693147180559945,"G",425.373959121877,0,0,0,33.5158523908524
"208",706,"G706R","MAPT",2,"","17:44101376:G:A","P10636",527.170731707317,"Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)",0.693147180559945,"G",425.373959121877,0,0,0,33.5158523908524
"209",706,"G706R","MAPT",0.1,"P","17:44101376:G:C","P10636",527.170731707317,"Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)",-2.30258509299405,"G",425.373959121877,0,0,0,33.5158523908524
"210",706,"G706R","MAPT",0.1,"P","17:44101376:G:A","P10636",527.170731707317,"Loss of ubiquitination at K702 (P = 0.0303); Gain of solvent accessibility (P = 0.0306); Gain of MoRF binding (P = 0.0374); Loss of loop (P = 0.1242); Gain of disorder (P = 0.1532)",-2.30258509299405,"G",425.373959121877,0,0,0,33.5158523908524
"211",707,"A707V","MAPT",1,"","17:44101380:C:T","P10636",293.317073170732,"Loss of ubiquitination at K712 (P = 0.0591); Loss of disorder (P = 0.0978); Loss of loop (P = 0.1242); Gain of sheet (P = 0.1945); Loss of phosphorylation at T703 (P = 0.1953)",0,"A",382.513247539743,0,0,0,14.0790020790021
"212",715,"V715A","MAPT",1,"","17:44101404:T:C","P10636",205.621951219512,"Gain of disorder (P = 0.0749); Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09); Gain of glycosylation at S713 (P = 0.1589); Gain of phosphorylation at S717 (P = 0.1749)",0,"V",568.242997728993,0.162,0,0.142,134.33316008316
"213",715,"V715M","MAPT",1,"","17:44101403:G:A","P10636",254.341463414634,"Loss of sheet (P = 0.0817); Gain of relative solvent accessibility (P = 0.09); Gain of disorder (P = 0.1023); Gain of solvent accessibility (P = 0.1045); Gain of phosphorylation at T720 (P = 0.1113)",0,"V",568.242997728993,0.162,0,0.142,134.33316008316
"214",723,"R723Q","MAPT",1,"","17:44101428:G:A","P10636",127.670731707317,"Loss of phosphorylation at S726 (P = 0.0591); Gain of glycosylation at T720 (P = 0.0671); Gain of relative solvent accessibility (P = 0.1066); Loss of sheet (P = 0.1907); Loss of catalytic residue at R723 (P = 0.1985)",0,"R",298.379258137774,0,0,0,69.4831081081081
"215",723,"R723W","MAPT",0.1,"P","17:44101427:C:T","P10636",342.036585365854,"Loss of disorder (P = 0.0292); Loss of phosphorylation at S726 (P = 0.0504); Gain of glycosylation at T720 (P = 0.1114); Gain of sheet (P = 0.1208); Gain of catalytic residue at N727 (P = 0.1329)",-2.30258509299405,"R",298.379258137774,0,0,0,69.4831081081081
"216",723,"R723W","MAPT",1,"","17:44101427:C:T","P10636",342.036585365854,"Loss of disorder (P = 0.0292); Loss of phosphorylation at S726 (P = 0.0504); Gain of glycosylation at T720 (P = 0.1114); Gain of sheet (P = 0.1208); Gain of catalytic residue at N727 (P = 0.1329)",0,"R",298.379258137774,0,0,0,69.4831081081081
"217",727,"N727H","MAPT",1,"","17:44101439:A:C","P10636",78.9512195121951,"Gain of sheet (P = 0.1208); Gain of relative solvent accessibility (P = 0.1259); Gain of phosphorylation at S729 (P = 0.1455); Gain of solvent accessibility (P = 0.199); Loss of loop (P = 0.2237)",0,"N",372.459500378501,0,0,0,52.4077442827443
"218",730,"S730F","MAPT",1,"","17:44101449:C:T","P10636",205.621951219512,"Loss of disorder (P = 0.0015); Loss of glycosylation at T731 (P = 0.0404); Loss of phosphorylation at S730 (P = 0.0514); Loss of loop (P = 0.0986); Gain of relative solvent accessibility (P = 0.1259)",0,"S",483.050719152157,0.074,0,0.017,10.6275987525987
"219",731,"T731A","MAPT",2,"","17:44101451:A:G","P10636",49.719512195122,"Loss of glycosylation at T731 (P = 0.016); Loss of sheet (P = 0.1158); Gain of catalytic residue at T731 (P = 0.1283); Gain of relative solvent accessibility (P = 0.1571); Loss of stability (P = 0.1983)",0.693147180559945,"T",460.297501892506,0,0,0,88.1933471933472
"220",732,"G732S","MAPT",3,"","17:44101454:G:A","P10636",371.268292682927,"Gain of phosphorylation at G732 (P = 0.0369); Gain of disorder (P = 0.0682); Loss of sheet (P = 0.0817); Gain of glycosylation at G732 (P = 0.1124); Loss of stability (P = 0.1246)",1.09861228866811,"G",551.310370931113,0.211,0,0.085,10.2642931392931
"221",735,"D735N","MAPT",2,"","17:44101463:G:A","P10636",312.80487804878,"Gain of catalytic residue at D735 (P = 0.0237); Loss of stability (P = 0.069); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.1303); Loss of phosphorylation at S733 (P = 0.1345)",0.693147180559945,"D",432.78198334595,0,0,0,106.176975051975
"222",736,"M736T","MAPT",1,"","17:44101467:T:C","P10636",186.134146341463,"Gain of glycosylation at M736 (P = 0.017); Loss of sheet (P = 0.0457); Gain of relative solvent accessibility (P = 0.0479); Gain of phosphorylation at M736 (P = 0.0681); Loss of stability (P = 0.0714)",0,"M",387.80469341408,0,0,0,102.543918918919
"223",736,"M736V","MAPT",1,"","17:44101466:A:G","P10636",137.414634146341,"Gain of catalytic residue at M736 (P = 0.0184); Gain of sheet (P = 0.0827); Loss of disorder (P = 0.1706); Loss of phosphorylation at S739 (P = 0.1899); Gain of glycosylation at S733 (P = 0.2538)",0,"M",387.80469341408,0,0,0,102.543918918919
"224",741,"Q741K","MAPT",4,"","17:44101481:C:A","P10636",575.890243902439,"Gain of solvent accessibility (P = 0.0071); Gain of ubiquitination at Q741 (P = 0.009); Gain of relative solvent accessibility (P = 0.0166); Gain of glycosylation at Q741 (P = 0.0701); Gain of phosphorylation at S739 (P = 0.1171)",1.38629436111989,"Q",557.660105980318,0.142,0,0.122,18.0753638253638
"225",743,"A743T","MAPT",3,"","17:44101487:G:A","P10636",78.9512195121951,"Gain of glycosylation at A743 (P = 0.0054); Gain of relative solvent accessibility (P = 0.09); Gain of loop (P = 0.1069); Gain of solvent accessibility (P = 0.1683); Gain of helix (P = 0.1736)",1.09861228866811,"A",280.91748675246,0,0,0,52.4077442827443
"226",744,"T744M","MAPT",2,"","17:44101491:C:T","P10636",566.146341463415,"Gain of helix (P = 0.0199); Loss of loop (P = 0.0288); Loss of glycosylation at T744 (P = 0.0314); Loss of phosphorylation at T744 (P = 0.1475); Gain of solvent accessibility (P = 0.199)",0.693147180559945,"T",446.010598031794,0,0,0,12.262474012474
"227",746,"A746T","MAPT",1,"","17:44101496:G:A","P10636",78.9512195121951,"Loss of helix (P = 0.0167); Gain of relative solvent accessibility (P = 0.0215); Gain of loop (P = 0.024); Gain of solvent accessibility (P = 0.0456); Gain of phosphorylation at A746 (P = 0.0884)",0,"A",460.297501892506,0,0,0,1
"228",748,"E748K","MAPT",1,"","17:44101502:G:A","P10636",137.414634146341,"Gain of ubiquitination at E748 (P = 0.0101); Gain of MoRF binding (P = 0.024); Gain of helix (P = 0.062); Loss of loop (P = 0.0804); Gain of relative solvent accessibility (P = 0.0999)",0,"E",505.274791824375,0.128,0,0.023,38.0571725571725
"229",752,"S752F","MAPT",1,"","17:44101515:C:T","P10636",225.109756097561,"Loss of disorder (P = 0); Loss of ubiquitination at K755 (P = 0.0353); Gain of methylation at K755 (P = 0.0373); Loss of phosphorylation at S752 (P = 0.051); Gain of catalytic residue at S752 (P = 0.173)",0,"S",318.486752460257,0,0,0,11.1725571725571
